INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,669,845 | -17.7% | 70,452 | +0.0% | 0.46% | -24.5% |
| Q2 2023 | $4,460,134 | +3.1% | 70,438 | -11.8% | 0.61% | +4.6% |
| Q1 2023 | $4,324,744 | +48.0% | 79,866 | +44.7% | 0.59% | +23.9% |
| Q4 2022 | $2,921,660 | +365.2% | 55,209 | +309.2% | 0.47% | +397.9% |
| Q3 2022 | $628,000 | +193.5% | 13,493 | +116.6% | 0.10% | +630.8% |
| Q4 2019 | $214,000 | -77.9% | 6,229 | -95.2% | 0.01% | -77.6% |
| Q3 2019 | $969,000 | +65.1% | 129,741 | +187.0% | 0.06% | +65.7% |
| Q2 2019 | $587,000 | -75.9% | 45,204 | -60.9% | 0.04% | -57.3% |
| Q1 2018 | $2,435,000 | +25.5% | 115,700 | -13.6% | 0.08% | +46.4% |
| Q4 2017 | $1,940,000 | +81.3% | 133,954 | +97.6% | 0.06% | +60.0% |
| Q3 2017 | $1,070,000 | +10.3% | 67,800 | -13.2% | 0.04% | -10.3% |
| Q2 2017 | $970,000 | -34.5% | 78,100 | -14.3% | 0.04% | -50.0% |
| Q1 2017 | $1,482,000 | +7.5% | 91,184 | -0.2% | 0.08% | -13.3% |
| Q4 2016 | $1,379,000 | – | 91,357 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |